Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Liliana Dalurzo, Mercedes; Avilés‐Salas, Alejandro; Augusto Soares, Fernando; Hou, Yingyong; Li, Yuan; М. Строганова, А.; Öz, Büğe; Abdillah, Arif; Wan, Hui; Choi, Yoon‐La

doi:10.2147/ott.s313669

Public

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets

Published in OncoTargets and Therapy • Aug 31, 2021

Authors:

Mercedes Liliana Dalurzo

Alejandro Avilés‐Salas

Fernando Augusto Soares

Abstract

Abstract: The treatment of patients with advanced non-small-cell lung cancer (NSCLC) in recent years has been increasingly guided by biomarker testing. Testing has centered on driver genetic alterations involving the epidermal growth factor receptor ( EGFR ) and anaplastic lymphoma kinase ( ALK ) re...

Subject

Anaplastic lymphoma kinase

Lung cancer

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!